CN109912663B - Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof - Google Patents

Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof Download PDF

Info

Publication number
CN109912663B
CN109912663B CN201910164735.0A CN201910164735A CN109912663B CN 109912663 B CN109912663 B CN 109912663B CN 201910164735 A CN201910164735 A CN 201910164735A CN 109912663 B CN109912663 B CN 109912663B
Authority
CN
China
Prior art keywords
reaction
formula
compound shown
compound
molar ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910164735.0A
Other languages
Chinese (zh)
Other versions
CN109912663A (en
Inventor
游书力
王少博
顾庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Priority to CN201910164735.0A priority Critical patent/CN109912663B/en
Publication of CN109912663A publication Critical patent/CN109912663A/en
Application granted granted Critical
Publication of CN109912663B publication Critical patent/CN109912663B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses an oxygen-linked cyclopentadiene rhodium complex, and a preparation method, an intermediate and application thereof. The structure of the rhodium complex is shown as the formula (R)a) -Rh-K or formula (S)a) -Rh-K. The rhodium complex of the invention shows higher yield and enantioselectivity in the catalytic Heck coupling reaction.

Description

Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof
Technical Field
The invention relates to an oxygen-linked cyclopentadiene rhodium complex, a preparation method, an intermediate and application thereof.
Background
The C-H bond functionalization reaction catalyzed by pentamethylcyclopentadiene metal (such as rhodium) complex can efficiently construct carbon-carbon bond and carbon heterobond, and is widely applied to chemical synthesis. However, until the last few years, there have been major breakthroughs in the asymmetric C-H bond functionalization reactions catalyzed by these complexes, in particular with rhodium and iridium. Ward and Rovis group succeeded in synthesizing biotinylated [ Cp Rh (III) 2012]The complex can be successfully applied to asymmetric C-H bond functionalization reaction [ T.K.hyster, L ] by combining the complex with streptavidin.
Figure GDA0002045120260000011
T.R.Ward,T.Rovis,Science 2012,338,500-503]. However, the synthesis of the catalyst is complex, and the reaction application range is not ideal. At approximately the same time, the Cramer group successfully bound the tartaric acid derivative backbone to cyclopentadiene, synthesizing a series of C2-symmetric cyclopentadiene ligands and applying them to the synthesis of rhodium complexes. The rhodium complex can efficiently and highly enantioselectively catalyze the hydroarylation reaction of the benzohydroxamic acid derivatives [ B.Ye, N.Cramer, Science 2012,338, 504-]. Subsequently, the panel in turn applied the binaphthyl backbone to the synthesis of C2-symmetric cyclopentadienyl ligands, and theyThe corresponding rhodium complex has wider application value in the reaction of the asymmetric C-H bond functionalization [ (a) Ye, B ]; cramer, n.j.am.chem.soc.2013,135,636, (b) Ye, b.; donets, p.a.; cramer, n.angelw.chem., int.ed.2014,53,507.(c) Ye, b.; cramer, n.angelw.chem., int.ed.2014,53,7896.(d) Zheng, j.; you, s. -l.angelw.chem., int.ed.2014,53,13244.(e) Ye, b.; cramer, n.synlett 2015,26,1490-1495 (f) Zheng, j.; wang, S. -B.; zheng, c.; you, S. -L.J.am.chem.Soc.2015,137,4880.]. Moreover, such cyclopentadienyl ligands have a wide variety of uses in other metal complexes [ (a) Song, g.; o, w.w.n.; hou, z.j.am.chem.soc.2014,136,12209.(b) Dieckmann, m.; jang, y. -s.; the amount of the Cramer compound is,N.Angew.Chem.Int.Ed.2015,54,12149.(c)Kossler, D;Cramer,N.J.Am.Chem.Soc.2015,137,12478.]. In 2016, the Youli group designed and synthesized a series of cyclopentadiene ligands based on a spiro chiral framework, which acted with metal rhodium to form rhodium complexes and showed very good catalytic effects in asymmetric C-H bond activation reactions [ (a) Zheng, J.; cui, w. -j.; zheng, c.; you, S. -L.J.am.chem.Soc.2016,138,5242.(b) Zheng, J.; wang, S. -B.; zheng, c.; you, s. -l.angelw.chem.int.ed.2017, 56,4540.(c) Li, t.; zhou, c.; yan, x.; wang, j.angelw.chem.int.ed.2018, 57,4048.]. In recent years, there are also few reports on the synthesis of novel chiral cyclopentadiene frameworks or the post-modification of existing frameworks in (a) Jia, z. -j.; merten, c.; gontla, R.; daniliuc, c.g.; antoinchick, a.p.; waldmann, h.angelw.chem.int.ed.2017, 56,2429.(b) Wang, s. -g.; park, s.h.; cramer, n.angelw.chem.int.ed.2018, 57,5459.(c) Sun, y.; cramer, n.chem.sci.,2018,9,2981.]. However, the backbone of the current cyclopentadienyl ligands is still relatively rare overall.
Disclosure of Invention
The invention aims to solve the technical problem of providing an oxygen-linked cyclopentadiene rhodium complex, and a preparation method, an intermediate and application thereof. The cyclopentadiene ligand in the rhodium complex has a brand-new oxygen bridge structure. The rhodium complex of the invention shows higher yield and enantioselectivity in the catalytic Heck coupling reaction.
The invention provides a compound of formula(Ra) -Rh-K or formula (S)a) -Rh-K:
Figure GDA0002045120260000021
wherein R is1And R1aEach independently is H, C1-C8Alkyl (e.g. methyl), substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12Aryl (e.g., phenyl);
R2and R2aEach independently is H, C1-C8Alkyl (e.g. methyl or ethyl), substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12Aryl (e.g., phenyl);
R3and R3aEach independently is H, C1-C8Alkyl radical, C1-C8Alkoxy (e.g. methoxy or ethoxy), substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted C6-C12Aryl (e.g. phenyl), substituted or unsubstituted C6-C12Aryloxy (e.g. phenoxy), or substituted or unsubstituted-O- (C)1-C3Alkyl group) - (C6-C12Aryl) (e.g., benzyloxy);
said substituted C3-C8Cycloalkyl, substituted C6-C12Aryl, substituted C6-C12Aryloxy and substituted-O- (C)1-C3Alkyl group) - (C6-C12Aryl) means substituted by one or more C1-C8Alkyl groups are substituted.
At R1、R2、R3、R1a、R2aAnd R3aIn (b), the C1-C8The alkyl groups may each independently be C1-C4Alkyl radicals, such as the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl radical, and also methyl or ethyl radicals.
At R1、R2、R3、R1a、R2aAnd R3aIn (b), the C3-C8The cycloalkyl groups may each independently be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
At R1、R2、R3、R1a、R2aAnd R3aIn (b), the C6-C12Aryl, substituted or unsubstituted C6-C12C in aryloxy6-C12Aryl and-O- (C)1-C3Alkyl group) - (C6-C12C in aryl)6-C12Aryl groups may each independently be phenyl or naphthyl, for example phenyl.
At R3And R3aIn (b), the C1-C8The alkoxy groups may each independently be C1-C4Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
In some embodiments of the invention, the compound is represented by formula (R)a) In the compounds represented by-Rh-K, R1Is C1-C8Alkyl, substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12Aryl, preferably C1-C8An alkyl group.
In some embodiments of the invention, the compound is represented by formula (S)a) In the compounds represented by-Rh-K, R1aIs C1-C8Alkyl, substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12Aryl, preferably C1-C8An alkyl group.
In the formula (R)a) In the compounds represented by-Rh-K, R2Preferably H or C1-C8An alkyl group.
In the formula (S)a) In the compounds represented by-Rh-K, R2aPreferably H or C1-C8An alkyl group.
In the formula(Ra) In the compounds represented by-Rh-K, R3Preferably C1-C8An alkoxy group.
In the formula (S)a) In the compounds represented by-Rh-K, R3aPreferably C1-C8An alkoxy group.
In some embodiments of the invention, the compound is represented by formula (R)a) In the compounds represented by-Rh-K, R1Is C1-C8An alkyl group;
R2is H or C1-C8An alkyl group;
R3is C1-C8An alkoxy group.
In some embodiments of the invention, the compound is represented by formula (S)a) In the compounds represented by-Rh-K, R1aIs C1-C8An alkyl group;
R2ais H or C1-C8An alkyl group;
R3ais C1-C8An alkoxy group.
In some embodiments of the invention, the compound is represented by formula (R)a) The compounds of-Rh-K are
Figure GDA0002045120260000041
In some embodiments of the invention, the formula is (S)a) The compounds of-Rh-K are
Figure GDA0002045120260000051
The invention also provides a compound as described above as formula (R)a) A method for preparing a compound represented by-Rh-K, comprising the steps of: in an organic solvent, the phenylacetic acid methyl ester compound is mixed with [ Rh (cod) Cl]2The following coordination reaction is carried out in the presence of a base to obtain a compound represented by the formula (R)a) A compound represented by-Rh-K; the methyl phenylacetate compound is shown as a formula (R)a) A compound of formula (R) I-Ca)-A compound of I-D or a mixture of both; wherein R is1、R2And R3The definition of (a) is as described above,&represents chirality of carbon atoms in R configuration, S configuration or a mixture of the two; # denotes that the chirality of the carbon atom is R configuration, S configuration, or a mixture of both;
Figure GDA0002045120260000061
the conditions for the coordination reaction may be conventional in the art for such reactions, and the following conditions are preferred in the present invention.
In the coordination reaction, the organic solvent may be an aromatic hydrocarbon solvent, such as toluene. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the methyl phenylacetate compound in the organic solvent can be 0.01-1 mol/L.
In the coordination reaction, the [ Rh (cod) Cl ] is]2The molar ratio to the methyl phenylacetate compound may be from 0.4 to 1:1, for example from 0.5 to 0.7: 1.
In the coordination reaction, the base may be an alkali metal hydroxide, such as potassium hydroxide. The base may be used in an amount conventional to such reactions in the art, for example the molar ratio of the base to the methyl phenylacetate compound may be from 1 to 5:1, for example from 2 to 4: 1.
The reaction temperature of the coordination reaction may be 20 to 100 deg.C (e.g., 60 to 80 deg.C).
The operation of the coordination reaction may be conventional in the art for such reactions. The progress of the coordination reaction can be monitored by conventional testing methods in the art (e.g., TLC, HPLC, GC, or NMR), and is generally determined as the end point of the reaction when the methyl phenylacetate compound is no longer reacted.
As shown in formula (R)a) The preparation method of the compound represented by-Rh-K can further comprise the following steps: in an organic solvent, the cyclopentadiene compound and methyl benzoylformate react in n-butyl lithium and diethylCarrying out addition reaction as shown in the specification in the presence of aluminum chloride to obtain a product; the cyclopentadiene compound is shown as a formula (R)a) A compound represented by formula (I-A), formula (R)a) -a compound represented by I-B or a mixture of both;
when the cyclopentadiene compound is shown as the formula (R)a) When the compound is a compound shown as the formula (R)a) -a compound of formula I-C;
when the cyclopentadiene compound is shown as the formula (R)a) When the compound is a compound shown as the formula (I-B), the product is shown as the formula (R)a) -a compound of formula I-D;
when the cyclopentadiene compound is shown as the formula (R)a) A compound represented by the formula (I-A) and a compound represented by the formula (R)a) When the compound shown as the formula I-B is a mixture, the product is shown as the formula (R)a) A compound represented by the formula (I-C) and a compound represented by the formula (R)a) -a mixture of compounds represented by I-D;
Figure GDA0002045120260000071
the conditions for the addition reaction may be conventional in the art for such reactions, and the following conditions are preferred in the present invention.
In the addition reaction, the organic solvent may be an ether solvent, such as tetrahydrofuran. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the cyclopentadiene compound in the organic solvent may be 0.01 to 1 mol/L.
In the addition reaction, the molar ratio of the methyl benzoylformate to the cyclopentadiene compound can be 1-2:1, for example 1.5-1.8: 1.
In the addition reaction, the molar ratio of the n-butyllithium to the cyclopentadiene compound may be 1.1 to 2:1, for example, 1.5 to 1.8: 1.
In the addition reaction, the molar ratio of the diethyl aluminum chloride to the cyclopentadiene compound may be 1.1 to 2:1, for example, 1.5 to 1.8: 1.
The reaction temperature of the addition reaction may be from-30 ℃ to-10 ℃ (e.g., -15 ℃ to-10 ℃).
The operation of the addition reaction can be the conventional operation of the reaction in the field, for example, after the cyclopentadiene compound is reacted with n-butyl lithium, diethyl aluminum chloride is added, after a period of reaction, methyl benzoylformate is added, and the reaction is continued.
The progress of the addition reaction can be monitored by conventional testing methods in the art (e.g., TLC, HPLC, GC, or NMR), and is generally determined as the end point of the reaction when the cyclopentadiene compound is no longer reacted.
The invention also provides a compound as described above as formula (S)a) A process for the preparation of the compound represented by the formula (R) only by reacting a compound represented by the formula (R) as described abovea) The reactant in the preparation method of the compound shown as-Rh-K is replaced by dinaphthalene with chiral axis of SaThe corresponding compound of the configuration is sufficient.
The invention also provides a compound shown as the formula I-A or I-B,
Figure GDA0002045120260000081
wherein R is1、R2And R3Is as defined above;
indicates that the axial chirality of binaphthyl is RaConfiguration or SaConfiguration;&indicates that the chirality of the carbon atom is R configuration, S configuration or the mixture of the two.
In some embodiments of the invention, the compound of formula I-A is
Figure GDA0002045120260000082
Figure GDA0002045120260000091
In some embodiments of the invention, the compound of formula I-B is
Figure GDA0002045120260000092
The invention also provides a preparation method of the compound shown as the formula I-A or I-B, which comprises the following steps: in an organic solvent, carrying out a reduction reaction shown as the following on a compound shown as a formula II in the presence of lithium aluminum hydride to obtain a compound shown as a formula I-A and/or I-B; wherein R is1、R2、R3A, b, and&is as defined above;
Figure GDA0002045120260000101
the conditions for the reduction reaction may be conventional in the art, and the following conditions are preferred in the present invention.
The reduction is preferably carried out under a gas (e.g. argon) blanket.
In the reduction reaction, the organic solvent may be an ether solvent, such as tetrahydrofuran. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula II in the organic solvent can be 0.01-1 mol/L.
In the reduction reaction, the molar ratio of the lithium aluminum hydride to the compound shown in the formula II can be 5-20:1 (for example, 8-12: 1).
The reduction is preferably carried out in the presence of a Lewis acid. The lewis acid may be a lewis acid conventional to such reactions in the art, such as aluminum trichloride. The amount of Lewis acid may be any amount conventionally used in such reactions in the art, for example the molar ratio of the Lewis acid to the compound of formula II may be from 1 to 10:1 (e.g., from 4 to 6: 1).
The reaction temperature of the reduction reaction may be 10 to 70 deg.C (e.g., 30 to 50 deg.C).
The progress of the reduction reaction can be monitored by conventional testing methods in the art (e.g., TLC, HPLC, GC, or NMR), and is generally determined as the end point of the reaction when the compound of formula II is no longer reacted.
The preparation method of the compound shown in the formula I-A or I-B can further comprise a preparation method of a compound shown in the formula II, and the preparation method of the compound shown in the formula II is method 1 or method 2:
the method 1 comprises the following steps: in an organic solvent, carrying out coupling reaction on a compound shown as a formula III and an organic zinc reagent or an organic boron reagent in the presence of a palladium catalyst to obtain a compound shown as a formula II; wherein the organic zinc reagent is Zn (R)2)2Or ZnR2Y, Y is chlorine, bromine or iodine (e.g. chlorine); the organic boron reagent is R2B(OH)2;R1、R2、R3A, b, and&is as defined above;
Figure GDA0002045120260000111
the method 2 comprises the following steps: in an organic solvent, carrying out an elimination reaction shown in the following formula on a compound shown in a formula III-2 in the presence of tert-butyl alcohol alkali metal salt and water to obtain a compound shown in a formula II; wherein R is2Is hydrogen; r1、R3A, b, and&is as defined above;
Figure GDA0002045120260000112
in the method 1, the conditions of the coupling reaction may be conventional in the art, and the following conditions are preferred in the present invention.
In the method 1, the coupling reaction is preferably performed under a gas (e.g., argon) shield.
In the method 1, in the coupling reaction, the organic solvent may be an ether solvent, such as dioxane. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula III in the organic solvent can be 0.01-1 mol/L.
In some embodiments of the invention, the method 1 is performed when R is2When the compound is alkyl, an organic zinc reagent is adopted to react with the compound shown in the formula III. In one embodiment of the invention, the organozinc reagent is ZnMe2. In one embodiment of the invention, the organozinc reagent is ZnEtCl.
In some embodiments of the invention, the method 1 is performed when R is2In the case of aryl, an organoboron reagent is used to react with the compound shown in formula III. In one embodiment of the invention, the organoboron reagent is PhB (OH)2
In the method 1, in the coupling reaction, the organic zinc reagent can be added to the reaction system in the form of a commercially available solution, for example, an n-hexane solution of the organic zinc reagent.
In the method 1, in the coupling reaction, the molar ratio of the organic zinc reagent to the compound shown in the formula III can be 2-8:1 (for example, 4-6: 1).
In the method 1, the molar ratio of the organoboron reagent to the compound represented by the formula III in the coupling reaction may be 2 to 8:1 (for example, 4 to 6: 1).
In the method 1, in the coupling reaction, the palladium catalyst may be a palladium catalyst conventional in the art, such as tetrakis (triphenylphosphine) palladium. The amount of the palladium catalyst may be that conventionally used in such reactions in the art, for example the molar ratio of the palladium catalyst to the compound of formula III may be 0.02 to 0.3:1 (e.g. 0.05 to 0.1: 1).
In the method 1, the reaction temperature of the coupling reaction may be 25 to 100 ℃ (e.g., 70 ℃ to 90 ℃).
In the method 1, the progress of the coupling reaction can be monitored by conventional testing methods in the art (such as TLC, HPLC, GC or NMR), and the reaction end point is generally determined when the compound represented by the formula III is no longer reacted.
In the method 2, the conditions of the elimination reaction can be conventional in the art, and the following conditions are preferred in the present invention.
In the method 2, the elimination reaction is preferably performed under a gas (e.g., argon) shield.
In the method 2, in the elimination reaction, the organic solvent may be a sulfone solvent, such as dimethyl sulfoxide. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula III-2 in the organic solvent can be 0.01-1 mol/L.
In the method 2, in the elimination reaction, the alkali metal salt of t-butanol may be sodium t-butoxide and/or potassium t-butoxide. In one embodiment of the present invention, the alkali metal salt of tert-butanol is potassium tert-butoxide. The alkali metal tert-butoxide may be used in amounts customary in the art for such reactions, for example the molar ratio of the alkali metal tert-butoxide to the compound of formula III-2 may be from 2.2 to 3.2:1 (e.g. from 3 to 3.2: 1).
In the elimination reaction in the method 2, the amount of water used may be an amount conventionally used in such reactions in the art, for example, the molar ratio of the water to the compound represented by the formula III-2 may be 10 to 100:1 (e.g., 30 to 40: 1).
In the method 2, the reaction temperature of the elimination reaction may be 25 to 100 ℃ (e.g., 60 ℃ to 80 ℃).
In the method 2, the progress of the elimination reaction can be monitored by a conventional test method in the art (such as TLC, HPLC, GC or NMR), and the reaction end point is generally determined when the compound represented by the formula III-2 is not reacted any more.
The method isThe method 1 can further comprise the following steps: in an organic solvent, mixing a compound shown as IV and R1Carrying out addition reaction on MgX as shown in the specification to obtain a compound shown in a formula III; wherein X is chlorine, bromine or iodine, R1、R3A, b, and&is as defined above;
Figure GDA0002045120260000131
in the method 1, the conditions of the addition reaction can be conventional in the art, and the following conditions are preferred in the present invention.
In the method 1, the addition reaction is preferably performed under a gas (e.g., argon) shield.
In the method 1, in the addition reaction, the organic solvent may be an ether solvent, such as diethyl ether.
In the method 1, the amount of the organic solvent used in the addition reaction is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula IV in the organic solvent can be 0.01-1 mol/L.
In the method 1, the addition reaction is carried out with the addition of R1The molar ratio of MgX to the compound of formula IV may be 1-2:1 (e.g., 1.5-2: 1).
In the method 1, the reaction temperature of the addition reaction may be-30 ℃ to 5 ℃ (e.g., -20 ℃ to 0 ℃).
In the method 1, the progress of the addition reaction can be monitored by conventional testing methods in the art (such as TLC, HPLC, GC or NMR), and the end point of the reaction is generally determined when the compound represented by the formula IV is no longer reacted.
The method 1 may further include the following steps: in an organic solvent, carrying out iodination reaction on a compound shown as a formula V and iodine in the presence of alkali to obtain a compound shown as a formula IV; wherein R is3Definition of (a) and (b)As described above;
Figure GDA0002045120260000141
in the method 1, the condition of the iodination reaction can be a conventional condition of the reaction in the field, and the following condition is preferred in the invention.
In the method 1, the iodination reaction is preferably performed under a gas (e.g., argon) shield.
In the method 1, in the iodination reaction, the organic solvent may be a mixed solvent of a nitrile solvent (e.g., acetonitrile) and a chlorinated hydrocarbon solvent (e.g., dichloromethane). In the mixed solvent, the volume ratio of the nitrile solvent to the chlorohydrocarbon solvent can be 0.8-1.2: 1. In one embodiment of the present invention, the organic solvent is a mixed solvent of acetonitrile and dichloromethane. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula V in the organic solvent can be 0.01-1 mol/L.
In the method 1, in the iodination reaction, the molar ratio of the iodine to the compound represented by the formula V can be 1-6:1 (e.g., 3-5: 1).
In the method 1, in the iodination reaction, the base may be an inorganic base, such as an alkali metal bicarbonate (e.g., sodium bicarbonate and/or potassium bicarbonate). The base may be added to the reaction system in the form of an aqueous solution. When the base is added to the reaction system in the form of an aqueous solution, the volume ratio of the aqueous solution to the organic solvent may be 1:10 to 30. In one embodiment of the invention, the base is sodium bicarbonate. In one embodiment of the present invention, the base is sodium bicarbonate, and the aqueous solution of sodium bicarbonate is added to the reaction system.
In the method 1, the reaction temperature of the iodination reaction may be 0 to 50 ℃ (e.g., 10 to 30 ℃).
In the method 1, the iodination reaction is preferably carried out in the absence of light.
In the method 1, the progress of the iodination reaction can be monitored by conventional testing methods in the art (such as TLC, HPLC, GC or NMR), and the end point of the reaction is generally determined when the compound represented by the formula V is no longer reacted.
The method 2 may further include the following steps: in an organic solvent, a compound shown as V and R1MgX is subjected to addition reaction as shown in the specification to obtain a compound shown in a formula III-2; wherein X is chlorine, bromine or iodine, R1、R3A, b, and&is as defined above;
Figure GDA0002045120260000151
in the method 2, the conditions of the addition reaction can be conventional in the field, and the following conditions are preferred in the invention.
In the method 2, the addition reaction is preferably performed under a gas (e.g., argon) shield.
In the method 2, in the addition reaction, the organic solvent may be an ether solvent, such as diethyl ether.
In the method 2, in the addition reaction, the amount of the organic solvent used may not be particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula V in the organic solvent can be 0.01-1 mol/L.
In the method 2, the addition reaction is carried out with the addition of R1The molar ratio of MgX to the compound shown as V may be from 1 to 2:1 (e.g., from 1.5 to 2: 1).
In the method 2, the reaction temperature of the addition reaction may be-30 ℃ to 5 ℃ (e.g., -20 ℃ to 0 ℃).
In the method 2, the progress of the addition reaction can be monitored by conventional testing methods in the art (such as TLC, HPLC, GC or NMR), and the end point of the reaction is generally determined when the compound represented by the formula V is no longer reacted.
The method 1 or the method 2 can further comprise the following steps: in an organic solvent, carrying out cyclization reaction on a compound shown as a formula VI and a cobalt carbonyl reagent in a carbon monoxide atmosphere to obtain a compound shown as a formula V;
Figure GDA0002045120260000161
wherein R is3And are as defined above.
The conditions for the ring-closure reaction may be conventional in the art, and the following conditions are preferred in the present invention.
The cyclization reaction is preferably carried out under a gas (e.g., argon) blanket.
In the cyclization reaction, the organic solvent may be an aromatic hydrocarbon solvent, such as toluene. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula VI in the organic solvent can be 0.01-1 mol/L.
In the cyclization reaction, the cobalt carbonyl reagent can be BrCCo3(CO)9. The molar ratio of the cobalt carbonyl reagent to the compound of formula VI can be from 0.05 to 0.2:1 (e.g., from 0.1 to 0.2: 1).
In the cyclization reaction, the pressure of the carbon monoxide may be 10 to 30atm (e.g., 20 to 30 atm).
The reaction temperature of the cyclization reaction may be from 50 ℃ to 130 ℃ (e.g., from 90 ℃ to 120 ℃).
The progress of the ring closure reaction can be monitored by conventional testing methods in the art (e.g., TLC, HPLC, GC or NMR), and is generally determined as the end point of the reaction when the compound of formula VI is no longer reacted.
The method 1 or the method 2 can further comprise the following steps: reacting a compound shown as a formula VII with tert-butyl lithium in an organic solvent, and then reacting with trimethylchlorosilane in the presence of hexamethylphosphoric triamide to obtain a compound shown as a formula VI;
Figure GDA0002045120260000171
wherein R is3And are as defined above.
In the above-mentioned preparation method of the compound represented by the formula VI, each reaction condition may be a conventional condition of the same type of reaction in the art, and the following conditions are preferred in the present invention.
In the above-mentioned process for preparing the compound represented by the formula VI, each reaction is preferably carried out under a gas (e.g., argon) shield.
In the above method for preparing the compound represented by the formula VI, the organic solvent may be an ether solvent, such as tetrahydrofuran. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula VII in the organic solvent can be 0.01-1 mol/L.
In the reaction of the compound shown in the formula VII and the tert-butyl lithium, the molar ratio of the tert-butyl lithium to the compound shown in the formula VII can be 3-5:1 (such as 4-5: 1). The t-butyllithium may be added to the reaction system in the form of a commercially available solution, for example, a hexane solution of t-butyllithium, a pentane solution of t-butyllithium.
In the reaction of the compound shown as the formula VII and tert-butyl lithium, the reaction temperature can be-90 to-60 ℃, such as-80 to-70 ℃.
The reaction of the compound shown as the formula VII and tert-butyl lithium is directly carried out with trimethylchlorosilane in the presence of hexamethylphosphoric triamide without post-treatment. In one embodiment of the invention, the reaction of the compound of formula VII with tert-butyllithium is carried out after 30 minutes to 3 hours (e.g. 30 minutes to 1 hour) and without work-up is reacted directly with trimethylchlorosilane in the presence of hexamethylphosphoric triamide.
The molar ratio of trimethylchlorosilane to the compound of formula VII may be 3-5:1 (e.g., 4-5: 1).
The molar ratio of hexamethylphosphoric triamide to the compound of formula VII may be 3-5:1 (e.g. 4-5: 1).
In the reaction of the trimethylchlorosilane, the reaction temperature can be 10-30 ℃.
In the preparation method of the compound shown in the formula VI, the reaction operation can be the conventional operation of the same type of reaction in the field, for example: under the protection of gas, reacting the compound shown as the formula VII and tert-butyl lithium at-90 to-60 ℃ (for example at-80 to-70 ℃) for 30 minutes to 3 hours (for example, 30 minutes to 1 hour), adding trimethylchlorosilane and hexamethyl phosphoric triamide, and naturally heating to 10-30 ℃ for reaction.
In the above-described process for the preparation of the compound of formula VI, the progress of the reaction can be monitored by conventional methods of art (e.g., TLC, HPLC, GC or NMR).
The method 1 or the method 2 can further comprise the following steps: in an organic solvent, carrying out substitution reaction on a compound shown as a formula VIII and trichloroethylene in the presence of sodium hydride as shown in the specification to obtain a compound shown as a formula VII;
Figure GDA0002045120260000181
wherein R is3And are as defined above.
The conditions for the substitution reaction may be conventional in the art, and the following conditions are preferred in the present invention.
The substitution reaction is preferably carried out under a gas (e.g., argon) blanket.
In the substitution reaction, the organic solvent may be a sulfone solvent, such as dimethyl sulfoxide. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound shown in the formula VIII in the organic solvent can be 0.01-1 mol/L.
In the substitution reaction, the molar ratio of the trichloroethylene to the compound shown in the formula VIII can be 2-8:1 (such as 4-6:1, and further such as 5: 1).
In the substitution reaction, the molar ratio of the sodium hydride to the compound shown in the formula VIII can be 3-5:1 (such as 4-5: 1).
The substitution reaction may be carried out at a temperature of from 20 ℃ to 100 ℃ (e.g., from 50 ℃ to 70 ℃).
The operation of the substitution reaction may be conventional in the art for such reactions, for example: the compound shown as the formula VIII firstly reacts with sodium hydride, and then reacts with trichloroethylene. In one embodiment of the invention, the compound shown as the formula VIII reacts with sodium hydride at the temperature of 0-30 ℃ for 30 minutes to 2 hours, and then trichloroethylene is directly added for reaction.
The progress of the substitution reaction can be monitored by conventional testing methods in the art (e.g., TLC, HPLC, GC, or NMR), and is generally determined as the end point of the reaction when the compound of formula VIII is no longer reacted.
The compound shown as the formula I-A, the compound shown as the formula I-B or the mixture of the compound shown as the formula I-A and the compound shown as the formula I-B, which are prepared by the preparation method of the compound shown as the formula I-A or the formula I-B, can be used for preparing the compound shown as the formula (R)a) -Rh-K or formula (S)a) -Rh-K.
The invention also provides a compound shown as the formula II:
Figure GDA0002045120260000201
wherein R is1、R2、R3A, b, and&is as defined above.
The invention also provides a preparation method of the compound shown in the formula II, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound shown as the formula III:
Figure GDA0002045120260000202
wherein R is1、R3A, b, and&is as defined above.
The invention also provides a preparation method of the compound shown in the formula III, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound shown as the formula III-2:
Figure GDA0002045120260000203
wherein R is1、R3A, b, and&is as defined above.
The invention also provides a preparation method of the compound shown in the formula III-2, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound shown as the formula IV:
Figure GDA0002045120260000211
wherein R is3And are as defined above.
The invention also provides a preparation method of the compound shown in the formula IV, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound shown as the formula V:
Figure GDA0002045120260000212
wherein R is3And are as defined above.
The invention also provides a preparation method of the compound shown in the formula V, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound shown as the formula VI:
Figure GDA0002045120260000213
wherein R is3And are as defined above.
The invention also provides a preparation method of the compound shown in the formula VI, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound shown as the formula VII:
Figure GDA0002045120260000221
wherein R is3And are as defined above.
The invention also provides a preparation method of the compound shown in the formula VII, and each reaction condition is as described in the preparation method of the compound shown in the formula I-A or I-B.
The invention also provides a compound as described above as formula (R)a) -Rh-K or formula (S)a) Application of a compound represented by-Rh-K as a catalyst in preparation of a compound P by performing a coupling reaction of a compound A and a compound B as shown in the specification; wherein, # denotes the axial chirality of compound P, as in formula (R)a) When a compound represented by-Rh-K is used as a catalyst, @ denotes SaConfiguration; when the formula is (S)a) When a compound represented by-Rh-K is used as a catalyst, @ denotes RaConfiguration;
Figure GDA0002045120260000222
the invention also provides a preparation method of the compound P, which comprises the following steps: in an organic solvent, compound A and compound B are reacted as shown in the formula (R)a) -Rh-K or formula (S)a) Under the catalysis of a compound represented by-Rh-K, carrying out coupling reaction shown as the following in the presence of benzoyl peroxide, copper acetate and silver carbonate to obtain a compound P;
@ denotes axial chirality of compound P, as in formula (R)a) When a compound represented by-Rh-K is used as a catalyst, @ denotes SaConfiguration; when the formula is (S)a) When a compound represented by-Rh-K is used as a catalyst, @ denotes RaConfiguration;
Figure GDA0002045120260000231
in the preparation method of the compound P, the conditions of the coupling reaction can be conventional in the field, and the following conditions are preferred in the invention.
In the preparation method of the compound P, the coupling reaction is preferably performed under the protection of a gas (e.g., nitrogen or argon).
In the preparation method of the compound P, the organic solvent may be an alcohol solvent, such as methanol, in the coupling reaction. The amount of the organic solvent to be used is not particularly limited as long as the reaction is not affected. For example, the molar concentration of the compound A in the organic solvent may be 0.01 to 1 mol/L.
In the preparation method of the compound P, the molar ratio of the compound B to the compound a in the coupling reaction may be 1-2:1 (e.g., 1.2-1.4: 1).
In the preparation method of the compound P, in the coupling reaction, the molar ratio of the benzoyl peroxide to the compound A can be 0.01-0.5:1 (such as 0.05-0.1: 1).
In the preparation method of the compound P, the molar ratio of the copper acetate to the compound A in the coupling reaction can be 0.02-1.0:1 (such as 0.2-0.4: 1).
In the preparation method of the compound P, the molar ratio of the silver carbonate to the compound a in the coupling reaction may be 1.0-2.0:1 (e.g., 1.0-1.2: 1).
In the preparation method of the compound P, the coupling reaction is carried out in a formula shown in the specification (R)a) -Rh-K or formula (S)a) The molar ratio of the compound "represented by-Rh-K to the compound A may be 0.01 to 0.5:1 (e.g., 0.05 to 0.1: 1).
In the preparation method of the compound P, the reaction temperature of the coupling reaction can be 15-80 ℃ (such as 25-45 ℃).
In the preparation method of the compound P, the progress of the coupling reaction can be monitored by a conventional test method in the field (such as TLC, HPLC, GC or NMR), and the end point of the reaction is generally determined when the compound A is not reacted any more.
In the present invention, R is usedaAnd Sa(subscript a represents axis) chirality to distinguish it from the configuration of the chiral carbon atoms (R and S).
In the present invention, the term "alkyl" refers to a saturated, straight or branched chain, monovalent hydrocarbon radical having the specified number of carbon atoms, such as C1-C10Alkyl refers to alkyl groups having 1 to 10 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, tert-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl).
In the present invention, the term "alkoxy" refers to an alkyl group (alkyl as defined herein) attached to the rest of the molecule through an oxygen bridge.
In the present invention, the term "cycloalkyl" refers to a saturated monovalent cyclic hydrocarbon group having the specified number of ring carbon atoms, and the cycloalkyl group may be monocyclic or polycyclic (e.g., bicyclic and tricyclic), may be a fused, spiro and bridged ring structure. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, and cyclopentyl.
In the present invention, the term "aryl" refers to any stable monocyclic or polycyclic (e.g., bicyclic or tricyclic) carbocycle of up to 7 atoms in each ring, wherein at least one ring is aromatic. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, 2, 3-indanyl, biphenyl, phenanthryl, anthryl, or acenaphthenyl (acenaphthyl). It will be understood that where the aryl substituent is a bicyclic substituent and one of the rings is non-aromatic, the attachment is through an aromatic ring.
In the present invention, the term "substituted" or "substituent" means that one or more hydrogen atoms are replaced by the specified group. When the position of substitution is not indicated, the substitution may be at any position, but formation of a stable or chemically feasible chemical is permissible.
When any variable (e.g., R) occurs more than one time in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2R, the group may optionally be substituted with up to two R, and R in each case has the independent option that two R's may be the same or different. Furthermore, combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows: the rhodium complex of the invention shows higher yield and enantioselectivity in the catalytic Heck coupling reaction.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
Example 1: compound (R)a) -synthesis of K1:
Figure GDA0002045120260000251
step 1
Synthesis of (Ra) -VII-1: under the protection of argon, a 250mL three-necked bottle is dried and added with (R)a) -VIII-1(17.32g,50mmol) and DMSO (200mL) were dissolved with stirring at room temperature, NaH (8.0g,4.0equiv, 60%) was added to the system, and after completion of the addition, the reaction was carried out at room temperature for 30 minutes, and then chlorotrifluoroethylene (5.0equiv) was added to the system, and after completion of the addition, the reaction was carried out at 60 ℃. TLC monitored the reaction until the starting material disappeared. After the reaction is finished, stopping heating, cooling to room temperature, and saturating NH4Quenching reaction by Cl solution, extracting by ethyl acetate, washing by saturated sodium chloride solution, and anhydrous Na2SO4The organic phase was dried and the solvent removed under reduced pressure on a rotary evaporator and the residue was chromatographed on a silica gel column (PE/EtOAc. 5/1) to give the corresponding compound.
Figure GDA0002045120260000261
White foam, 80% yield.1H NMR(400MHz,CDCl3)δ7.81(d,J=8.0Hz,2H),7.47-7.38(m,2H),7.36(s,2H),7.21-7.11(m,4H),5.18(s,2H),4.04(s,6H);13CNMR(100MHz,CDCl3) δ 151.1,141.13,141.1,132.0,128.1,126.6,126.4,126.2,124.9,124.3,108.1,95.6, 56.1; IR (film) < v >max(cm-1) 3104,1666,1629,1596,1503,1460,1425,1391,1363,1328,1294,1271,1243,1196,1164,1151,1119,1075,1015,983,938,902,865,831,773,744,730,636,619; calculated value of elemental analysis C26H18Cl4O4(536.23) C, 58.24; h,3.38, found C, 58.11; h,3.53.[ alpha ]]D 29-22.0(c ═ 0.20, chloroform).
Step 2
Synthesis of (Ra) -VI-1: a100 mL single-neck bottle was dried under argon and compound (R) was addeda) VII-1(2.68g,5mmol) and THF (50mL) were stirred to make the system white and turbid, and placed under a dry cold acetone bath, a dry ice acetone bath and added dropwise to the systemtBuLi (17.3mL,1.3M in hexane,4.5equiv), after the addition of dry ice, was reacted for 1 hour in an acetone bath, and then added to the systemTMSCl (1.7mL,4.0equiv) and HMPA (3.4mL,4.0equiv) were added dropwise, and the system was naturally warmed to room temperature to react. During this time TLC monitored the reaction until the starting material disappeared. After the reaction is finished, water is added for quenching the reaction, ethyl acetate is used for extraction, saturated sodium chloride solution is used for washing, and anhydrous Na2SO4The organic phase is dried and the solvent is removed under reduced pressure on a rotary evaporator and the residue is chromatographed on a silica gel column (PE/DCM ═ 40/1) to give the corresponding product.
Figure GDA0002045120260000262
White foam, 81% yield.1H NMR(400MHz,CDCl3)δ7.82(d,J=8.0Hz,2H),7.47-7.42(m,2H),7.40(s,2H),7.22-7.14(m,4H),4.09(s,6H),-0.13(s,18H);13C NMR(100MHz,CDCl3) δ 149.4,143.2,132.0,128.0,126.7,126.4,126.0,124.7,122.3,108.8,105.4,56.0,37.3, 0.1; IR (film) < v >max(cm-1) 2958,2897,2178,1622,1597,1504,1461,1425,1393,1328,1295,1244,1198,1179,1145,1095,1011,974,928,834,748,696,635; calculated value of elemental analysis C32H34O4Si2(538.78) C, 71.34; h,6.36, found C, 71.41; h,6.34.[ alpha ]]D 29-24.5(c ═ 0.20, chloroform).
Step 3
(Ra) -synthesis of V-1: adding (R) into the high-pressure reaction kettle in sequencea)-VI-1(1.346g,2.5mmol,1.0equiv),BrCCo3(CO)9(130.2mg,0.25mmol,0.1equiv) and toluene (30mL), replacing CO gas for 3 times, finally charging CO (20atm) into the autoclave, reacting at 100 ℃ for 4 hours, cooling to room temperature after the reaction is completed, removing toluene by rotary evaporator under reduced pressure, and separating the residue by silica gel column chromatography (PE/DCE: 30/1) to obtain the corresponding product.
Figure GDA0002045120260000271
Yellow foam, 78% yield.1H NMR(400MHz,CDCl3)δ7.82(d,J=8.0Hz,2H),7.44(t,J=7.2Hz,2H),7.32(s,2H),7.29(d,J=7.2Hz,2H),7.20(t,J=7.6Hz,2H),4.01(s,6H),0.28(s,18H);13C NMR(100MHz,CDCl3) δ 203.8,172.7,151.8,142.1,132.4,126.9,126.7,126.6,126.4,126.1,124.4,114.6,107.8,55.3, -0.5; IR (film) < v >max(cm-1) 2954,2898,1681,1621,1592,1569,1505,1456,1425,1344,1298,1279,1242,1192,1160,1122,1081,1014,988,941,908,831,782,745,733,694,617; calculated value of elemental analysis C33H34O5Si2(566.79) C, 69.93; h,6.05. found C, 69.93; h,6.24.[ alpha ]]D 29(c ═ 0.20, chloroform).
Step 4
(Ra) Synthesis of IV-1: under the protection of argon, a 50mL single-neck bottle is filled with (R)a) V-1(992mg,1.75mmol,1.0equiv), acetonitrile (17mL,0.1M), dichloromethane (17mL,0.1M), saturated NaHCO3The aqueous solution (1.7mL,1.0M) was dissolved with stirring at room temperature, and I was added with stirring2(1.77g,6.99mmol,4.0equiv), after the addition, the reaction was carried out at room temperature with exclusion of light. TLC monitored the reaction until the starting material disappeared. After the reaction is completed, Na is added2S2O3Quenching the reaction with aqueous solution, extracting with DCM, washing with saturated sodium chloride solution, and adding anhydrous Na2SO4The organic phase was dried and the solvent was removed under reduced pressure on a rotary evaporator and the residue was chromatographed on a silica gel column (PE/DCM ═ 5/1) to give the corresponding product.
Figure GDA0002045120260000281
Red solid, 91% yield, m.p. ═ 207 ℃ decomposition.1H NMR(400MHz,CDCl3)δ7.86(d,J=8.4Hz,2H),7.52-7.45(m,2H),7.39(s,2H),7.27(d,J=8.4Hz,2H),7.24-7.18(m,2H),4.05(s,6H);13C NMR(100MHz,CDCl3) δ 183.5,168.8,150.7,141.4,132.7,127.1,126.9,126.5,126.5,125.3,124.8,108.2,66.6, 55.8; IR (film) < v >max(cm-1) 3052,2960,2932,2862,2828,2093,1715,1620,1577,1504,1457,1421,1342,1288,1245,1197,1165,1122,1080,1013,978,938,917,891,860,827,781,768,744,734,677,666,637,619; element classificationAnalysis of calculated value C27H16I2O5(674.22) C, 48.10; h,2.39, found C, 48.13; h,2.37.[ alpha ]]D 20300.0(c 0.10, chloroform).
Step 5
(Ra) -synthesis of III-1: under argon, a 50mL single-neck flask was charged with compound (R)a) IV-1(451.7mg,0.67mmol,1.0equiv) and Et2O (12mL), placing the system in an ice salt bath, dropwise adding MeMgI (0.33mL,1.0mmol,1.5equiv,3.0M) under the ice salt bath, placing the system in the ice salt bath for reaction for 1 hour after the addition is finished, and monitoring the reaction by TLC until the raw materials disappear and saturated NH disappears4Quenching reaction with Cl aqueous solution, extracting with ethyl acetate, washing with saturated sodium chloride solution, and adding anhydrous Na2SO4The organic phase is dried and the solvent is removed under reduced pressure on a rotary evaporator and the residue is chromatographed on a silica gel column (PE/DCM ═ 4/1) to give the corresponding compound.
Figure GDA0002045120260000291
Light yellow foam, 94% yield.1H NMR(400MHz,CDCl3)δ7.83(d,J=8.0Hz,2H),7.49-7.40(m,2H),7.35(d,J=2.2Hz,2H),7.25(d,J=11.2Hz,2H),7.19(d,J=6.4Hz,2H),4.03(s,6H),1.87(s,1H),1.31(s,3H);13C NMR(100MHz,CDCl3) δ 153.4,153.1,151.13,151.0,141.9,141.6,132.4,126.85,126.8,126.5,126.47,126.4,126.3,126.1,124.4,108.0,107.9,87.0,86.9,77.5,77.2,55.5, 25.5; IR (film) < v >max(cm-1) 3671,2972,2902,2118,1618,1584,1503,1454,1423,1342,1304,1242,1192,1151,1103,1077,1017,974,939,908,865,832,785,727,681,635; HRMS (ESI) calculated value C28H21I2O5[M+H]+690.9473; measured value 690.9470]D 26=+260.7(c=0.20,CH2Cl2)。
Step 6
(Ra) Synthesis of II-1: a50 mL single-neck bottle was dried under argon and added sequentially (R)a)-III-1(849mg,1.23mmol,1.0equiv),Pd(PPh3)4(71.2mg,0.062mmol,5mol%),ZnMe2(6.2mL,1.0M in hexane,5.0equiv) and dioxane (15mL), and after the addition, the system was placed in an oil bath at 80 ℃ for reaction. The reaction was monitored by TCL until disappearance of starting material. Cooling to room temperature, adding water to quench the reaction, extracting with ethyl acetate, washing with saturated aqueous sodium chloride solution, and adding anhydrous Na2SO4The organic phase is dried and the solvent is removed under reduced pressure on a rotary evaporator and the residue is chromatographed on a silica gel column (PE/DCM ═ 4/1) to give the corresponding compound.
Figure GDA0002045120260000292
Light yellow foam, 84% yield.1H NMR(400MHz,CDCl3)δ7.80(d,J=7.6Hz,2H),7.43-7.37(m,2H),7.32(s,2H),7.23-7.18(m,2H),7.17-7.11(m,2H),4.01(s,3H),3.99(s,3H),1.91(s,3H),1.90(s,3H),1.25(s,3H),1.17(s,1H);13C NMR(100MHz,CDCl3) δ 151.8,151.7,144.5,144.4,143.1,143.0,132.1,127.3,127.2,126.8,126.6,126.5,126.4,125.9,124.9,124.8,124.2,107.8,107.7,77.4,77.2,55.8,55.7,21.0,6.7, 6.6; IR (film) < v >max(cm-1) 2967,2933,2906,2851,2830,1649,1621,1596,1503,1457,1424,1381,1327,1243,1194,1163,1109,1077,1019,983,944,899,864,832,775,732,690,637,616; HRMS (ESI) calculated value C30H27O5[M+H]+467.1853; measured value 467.1850]D 19+173.4(c ═ 0.20, dichloromethane).
Step 7
(Ra) -I-1 and (R)a) -synthesis of I' -1: a50 mL single-neck flask was dried under argon and THF (10mL), LiAlH was added4(557.7mg,14.7mmol,10.0equiv), stirring in an ice-water bath, and adding AlCl3(979.7mg,7.35mmol,5.0equiv), smoking yellow smoke, stirring in ice water bath until no smoke is produced, heating to room temperature, and adding dropwise (R) at room temperaturea) Solution of II-1(685.8mg,1.47mmol,1.0equiv) in THF (10mL) was added and the reaction was completed at 40 ℃. TLC monitored the reaction until the starting material disappeared. Carefully adding dropwise water in ice water bath to quench the reaction, adding aqueous NaOH solution (1.5mL,2.0M,2.0equiv), stirringFor 10 min, ethyl acetate extraction, washing with saturated aqueous sodium chloride solution, anhydrous Na2SO4The organic phase is dried and the solvent is removed under reduced pressure on a rotary evaporator and the residue is chromatographed on a silica gel column (PE/DCM ═ 4/1) to give the corresponding compound. LCMS has two peaks of the same molecular weight.
Figure GDA0002045120260000301
White solid, 68% yield. m.p. 138-.1H NMR(400MHz,C6D6)δ7.68(d,J=8.0Hz,1H),7.64(d,J=8.0Hz,1H),7.52(d,J=8.4Hz,2H),7.27(dd,J=16.8,8.4Hz,2H),7.03(d,J=5.6Hz,2H),7.01-6.93(m,2H),3.42(s,3H),3.40(s,3H),3.36(t,J=7.6Hz,1H),2.20(s,3H),1.73(s,3H),1.25(d,J=7.6Hz,3H);13C NMR(100MHz,C6D6) δ 152.0,151.9,144.9,144.5,144.0,140.7,132.5,132.4,129.7,128.51,128.5,128.0,127.6,127.2,127.2,126.0,124.6,124.6,108.7,108.4,55.2,45.1,12.8,11.2, 9.9; IR (film) < v >max(cm-1) 2956,2923,2865,1660,1619,1597,1503,1458,1425,1385,1342,1289,1244,1216,1194,1163,1113,1020,993,949,892,863,831,775,746,680,636,620; HRMS (ESI) calculated value C30H27O4[M+H]+451.1904; measured value 451.1902]D 23+128.1(c 0.20, chloroform).
Step 8
(Ra) Synthesis of Rh-K1: dry 25mL reaction tube, add (R)a) -I-1 and (R)a) -I' -1(144.2mg,0.32mmol,1.0equiv), THF (3mL,0.1M), dissolved with stirring, placed in a cryosaline bath (-15 ℃) and added dropwise under the cryosaline bathnBuLi (0.2mL,0.48mmol,1.5equiv,2.4M in hexane), was reacted for 30 minutes in an ice salt bath, and Et was added dropwise to the system2AlCl (0.24mL,0.48mmol,1.5equiv,2.0M in THF), was maintained at-15 deg.C after addition and the reaction was continued for 30 minutes, followed by addition of methyl benzoylformate (78.8mg,0.48mmol,1.5equiv) dropwise to the system and continued under ice-salt bath. TLC monitored the reaction until the starting material disappeared. Adding water to quench the reaction, extracting with ethyl acetate, washing with saturated aqueous solution of sodium chlorideAnhydrous Na2SO4Drying and spin-drying through a silica gel column (PE/EtOAc ═ 50/1) gave the corresponding compound (containing a portion of methyl benzoylformate).
Another dry reaction tube is taken, the mixture obtained in the previous step is added under Ar, and [ Rh (cod) Cl]2(94.7mg,0.19mmol,0.6equiv), KOH (53.8mg,0.96mmol,3.0equiv) and toluene (3mL,0.1M), and reacted at 70 ℃ for 10 to 15 minutes. Stopping reaction, cooling to room temperature, performing rotary evaporator to remove toluene under reduced pressure, and collecting the residue as neutral Al2O3Column separation (toluene) to obtain the target compound.
Figure GDA0002045120260000311
Yellow foam, 37% yield.1H NMR(400MHz,C6D6)δ7.77(d,J=8.0Hz,1H),7.62(d,J=8.0Hz,1H),7.37(d,J=8.4Hz,1H),7.30-7.21(m,4H),6.95(s,1H),6.94-6.85(m,2H),3.69(s,3H),3.50(t,J=8.0Hz,2H),3.41(s,3H),3.09(t,J=8.0Hz,2H),2.46(s,3H),2.33-2.18(m,2H),2.13-2.02(m,2H),2.03-1.90(m,4H),1.86(s,3H),1.75(s,3H);13C NMR(100MHz,C6D6)δ152.4,151.8,146.4,145.3,132.5,132.3,128.6,128.4,127.2,127.13,127.1,127.0,126.1,126.0,125.0(d,JRh-C=4.6Hz),124.6,124.5,117.2(d,JRh-C=3.8Hz),108.3,108.1,86.7(d,JRh-C=3.6Hz),85.8(d,JRh-C=4.6Hz),85.3(d,JRh-C=3.8Hz),71.1(d,JRh-C=13.7Hz),70.6(d,JRh-C13.7Hz),55.3,55.0,33.1,32.8,9.3,9.1, 7.1; IR (film) < v >max(cm-1) 2918,2858,2820,1620,1597,1501,1458,1424,1377,1341,1325,1242,1210,1194,1163,1151,1112,1080,1053,1021,950,896,862,829,812,774,745,693,663,633,618; HRMS (MALDI-FT DHB) Calculation C38H37O4Rh[M]+660.1741; measured value 660.1763]D 24-324.8(c ═ 0.20, dichloromethane).
Example 2
Figure GDA0002045120260000321
Prepared according to the method of example 1. Yellow foam, final yield 62%.1H NMR(400MHz,C6D6)δ7.87(d,J=8.8Hz,1H),7.80(d,J=8.8Hz,1H),7.74(d,J=8.0Hz,1H),7.62(t,J=7.6Hz,2H),7.38(t,J=7.6Hz,2H),7.32(d,J=8.8Hz,1H),7.15-7.10(m,2H),6.96-6.87(M,2H),3.39(t,J=8.0Hz,2H),2.95(t,J=8.0Hz,2H),2.46-2.32(m,2H),2.19(s,3H),2.12-1.99(m,4H),1.85-1.73(m,2H),1.63(s,6H);13C NMR(100MHz,C6D6)δ155.0,153.9,133.8,133.6,131.9,131.8,131.1,131.0,128.6,128.5,128.4,127.2,127.1,127.06,126.9,126.3(d,JRh-C=4.4Hz),125.6,125.5,125.4(d,JRh-C=4.5Hz),124.0,122.2,117.7(d,JRh-C=3.8Hz),87.3(d,JRh-C=4.6Hz),84.5(d,JRh-C=4.0Hz),71.3(d,JRh-C=13.8Hz),70.6(d,JRh-C13.8Hz),34.0,32.0,9.2,8.6, 7.4; IR (film) < v >max(cm-1) 3055,2986,2960,2926,2907,2864,2817,1618,1588,1504,1456,1427,1380,1362,1324,1218,1151,1071,1050,1026,997,975,939,891,867,836,818,754,737,665,629; HRMS (MALDI-FT DHB) Calculation C36H33O2Rh[M]+600.1530; measured value 600.1545]D 28-121.2(c ═ 0.20, dichloromethane).
Example 3
Figure GDA0002045120260000331
Prepared according to the method of example 1. Yellow foam, final yield 37%. HRMS (MALDI-FT DHB) Calculation C40H41O4Rh[M]+688.2060; measured value 688.2062]D 24-330.8(c ═ 0.20, dichloromethane).
Example 4
Figure GDA0002045120260000332
Prepared according to the method of example 1. Yellow foam, and the final yield was 39%. HRMS (MALDI-FT DHB) Calculation C48H41O4Rh[M]+784.2060; measured value 784.2061]D 24-340.8(c ═ 0.20, dichloromethane).
Example 5
Figure GDA0002045120260000333
Prepared according to the method of example 1. Yellow foam, final yield 35%. HRMS (MALDI-FT DHB) Calculation C50H45O4Rh[M]+812.2373; measured value 812.2376]D 24-335.8(c ═ 0.20, dichloromethane).
Example 6
Figure GDA0002045120260000341
Prepared according to the method of example 1. Yellow foam, 31% yield in the last step. HRMS (MALDI-FT DHB) Calculation C48H41O2Rh[M]+752.2162; measured value 752.2163]D 24-331.8(c ═ 0.20, dichloromethane).
Example 7
Figure GDA0002045120260000342
A process according to example 1, wherein in step 6 ZnMe is reacted2The substitution was EtZnCl. Yellow foam, final yield 37%. HRMS (MALDI-FT DHB) Calculation C40H41O4Rh[M]+688.2060; measured value 688.2065]D 24-315.8(c 0.20, dichloromethane).
Example 8
Figure GDA0002045120260000343
A process according to example 1, wherein in step 6 ZnMe is reacted2Replacement by PhB (OH)2. Yellow foam, and the final yield was 33%. HRMS (MALDI-FT DHB) Calculation C48H41O4Rh[M]+784.2060; measured value 784.2063]D 24-355.8(c 0.20, dichloromethane).
Example 9
Figure GDA0002045120260000351
The method of example 1 was followed, wherein MeMgI was replaced with PhMgBr in step 5. Yellow foam, 31% yield in the last step. HRMS (MALDI-FT DHB) Calculation C43H39O4Rh[M]+722.1903; measured value 722.1905]D 24-332.8(c 0.20, dichloromethane).
Example 10
Figure GDA0002045120260000352
Step 1
Figure GDA0002045120260000353
(Ra) Preparation of III-2: the procedure as in step 5 of example 1, mixing (R)a) Replacement of-IV-1 by (R)a) -V-1. Yield 85%. HRMS (MALDI-FT DHB) Calculations C34H38O5Si2,[M]+582.2258; found 582.2253.
Step 2
Figure GDA0002045120260000361
(Ra) Preparation of II-2: under argon, a 50mL single-neck flask was charged with compound (R)a) III-2(512mg,1.0mmol,1.0equiv), DMSO (11.4mL), and H was added with stirring at room temperature2O(0.6mL),tBuOK (359mg,3.2mmol,3.2equiv), placing the system in oil bath at 70 ℃ for reaction after the addition is finished, monitoring the reaction by TLC until the raw materials disappear, cooling the system to room temperature, extracting with ethyl acetate/water, washing with saturated sodium chloride solution, and removing anhydrous Na2SO4The organic phase was dried and the solvent was removed under reduced pressure on a rotary evaporator and the residue was chromatographed on a silica gel column (PE/EtOAc. 5/1) to give the corresponding compound. Yield 80%. HRMS (MALDI-FTDHB) calculated value C28H22O5,[M]+438.1467; found 438.1464.
Step 3
Figure GDA0002045120260000362
(Ra) Preparation of I-2: the procedure as in step 7 of example 1, mixing (R)a) -II-1 is replaced by (R)a) -II-2. Yield 75%. HRMS (MALDI-FT DHB) Calculations C28H22O4,[M]+422.1518; found 422.1516.
Step 4
Figure GDA0002045120260000363
Prepared according to the method of step 8 of example 1. Will (R)a)-I-1,(Ra) -I' 1 is replaced by (R)a) -I-2. Yellow bubble, 32% yield. HRMS (MALDI-FT DHB) Calculation C36H33O4Rh[M]+632.1434; measured value 632.1436]D 24-341.4(c 0.20, dichloromethane).
Example 11
Figure GDA0002045120260000371
The synthesis according to example 10, wherein MeMgI is replaced by PhMgCl in step 1. Yellow foam, 31% yield in the last step. HRMS (MALDI-FT DHB) Calculation C41H35O4Rh[M]+694.1590; measured value 694.1593]D 24-331.2(c ═ 0.20, dichloromethane).
Example 12
Figure GDA0002045120260000372
By using (S)a) -VIII-1 substitution (R)a) VIII-1 Synthesis of (S) according to example 1a) -K1, yellow foam, final yield 36%. HRMS (MALDI-FT DHB) Calculation C38H37O4Rh[M]+660.1741; measured value 660.1763]D 24325.8(c 0.20, dichloromethane).
Effect example 1 (references angelw. chem. int.ed.2014,53,13244. j.am. chem. soc.2016,138,5242)
Figure GDA0002045120260000373
General reaction operation: the catalyst (0.01mmol) and benzoyl peroxide (2.4mg,0.01mmol) were dissolved in methanol (0.5mL) under nitrogen and reacted at room temperature for 30 min. Then, A (0.2mmol), B (0.24mmol), copper acetate (7.3mg,0.04mmol) and Ag were added in this order2CO3(55.2mg,0.2mmol) and methanol (0.5mL) at 25 ℃. After completion of the TLC tracing reaction, it was quenched with saturated sodium bicarbonate solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered and the solvent was removed under reduced pressure, and purified by column chromatography (petroleum ether/acetone-30/1). The ee value of product P was determined by HPLC.
Figure GDA0002045120260000381
Catalyst (R)a) Results of Rh-K1: yield 95%.1H NMR(400MHz,CDCl3) δ 8.94(d, J ═ 4.8Hz,1H),8.11-8.04(m,2H),8.01-7.73(m,5H),7.67-7.52(m,5H),7.42-7.32(m,4H),7.24(s,1H),7.21-7.13(m,1H),7.13-6.93(m,3H),6.77(d, J ═ 16.4Hz, 1H). HPLC conditions: chiral column Daicel Chiralcel AD-H (0.46 cm. times.25 cm), n-hexane/isopropanol 90/10(V/V), flow rate 1.0mL/min, detection wavelength 254nm, t (minor) 20.96min, t (major) 46.04min],96:4er;[α]D 22+560.1(c 0.22, chloroform).
TABLE 1 results of the experiment
Figure GDA0002045120260000382
Figure GDA0002045120260000391
Figure GDA0002045120260000401

Claims (36)

1. As shown in formula (R)a) -Rh-K or formula (S)a) -Rh-K:
Figure FDA0002913653440000011
wherein R is1And R1aEach independently is H, C1-C8Alkyl, substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12An aryl group;
R2and R2aEach independently is H, C1-C8Alkyl, substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12An aryl group;
R3and R3aEach independently is H, C1-C8Alkyl radical, C1-C8Alkoxy, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted C6-C12Aryl, substituted or unsubstituted C6-C12Aryloxy, or substituted or unsubstituted-O- (C)1-C3Alkyl group) - (C6-C12Aryl groups);
said substituted C3-C8Cycloalkyl, substituted C6-C12Aryl, substituted C6-C12Aryloxy and substituted-O- (C)1-C3Alkyl group) - (C6-C12Aryl) means substituted by one or more C1-C8Alkyl groups are substituted.
2. The compound of claim 1, wherein: at R1、R2、R3、R1a、R2aAnd R3aIn (b), the C1-C8Alkyl is independently C1-C4An alkyl group;
and/or, at R1、R2、R3、R1a、R2aAnd R3aIn (b), the C3-C8Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
and/or, at R1、R2、R3、R1a、R2aAnd R3aIn (b), the C6-C12Aryl, substituted or unsubstituted C6-C12C in aryloxy6-C12Aryl and-O- (C)1-C3Alkyl group) - (C6-C12C in aryl)6-C12Each aryl is independently phenyl or naphthyl;
and/or, at R3And R3aIn (b), the C1-C8Alkoxy is independently C1-C4An alkoxy group.
3. The compound of claim 1, wherein: at R1、R2、R3、R1a、R2aAnd R3aIn (b), the C1-C8Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, at R1、R2、R3、R1a、R2aAnd R3aIn (b), the C6-C12Aryl, substituted or unsubstituted C6-C12C in aryloxy6-C12Aryl and-O- (C)1-C3Alkyl group) - (C6-C12C in aryl)6-C12Each aryl group is independently phenyl;
and/or, at R3And R3aIn (b), the C1-C8Alkoxy is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
4. The compound of claim 1, wherein: at R1、R2、R3、R1a、R2aAnd R3aIn (b), the C1-C8Alkyl is independently methyl or ethyl.
5. The compound of claim 1, wherein: r1Is C1-C8Alkyl, substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12An aryl group;
and/or, R1aIs C1-C8Alkyl, substituted or unsubstituted C3-C8Cycloalkyl, or substituted or unsubstituted C6-C12An aryl group;
and/or, R2Is H or C1-C8An alkyl group;
and/or, R2aIs H or C1-C8An alkyl group;
and/or, R3Is C1-C8An alkoxy group;
and/or, R3aIs C1-C8An alkoxy group.
6. The compound of claim 1, wherein: r1Is C1-C8An alkyl group;
and/or, R1aIs C1-C8An alkyl group.
7. The compound of claim 1, wherein: as shown in formula (R)a) The compounds of-Rh-K are
Figure FDA0002913653440000021
Figure FDA0002913653440000022
Figure FDA0002913653440000031
And/or, said formula is (S)a) The compounds of-Rh-K are
Figure FDA0002913653440000032
Figure FDA0002913653440000033
8. A compound represented by formula I-A or I-B,
Figure FDA0002913653440000041
wherein R is1、R2And R3As defined in any one of claims 1 to 7;
indicates that the axial chirality of binaphthyl is RaConfiguration or SaConfiguration;&indicates that the chirality of the carbon atom is R configuration, S configuration or the mixture of the two.
9. The compound of claim 8, having formula I-a or I-B, wherein: the compound shown as the formula I-A is
Figure FDA0002913653440000042
Figure FDA0002913653440000043
And/or the compound shown as the formula I-B is
Figure FDA0002913653440000044
Figure FDA0002913653440000051
10. A process for the preparation of a compound of formula I-a or I-B as claimed in claim 8 or 9, comprising the steps of: in an organic solvent, carrying out a reduction reaction shown as the following on a compound shown as a formula II in the presence of lithium aluminum hydride to obtain a compound shown as a formula I-A and/or I-B; wherein R is1、R2、R3A, b, and&as defined in claim 8;
Figure FDA0002913653440000052
11. the method of claim 10, wherein: the reduction reaction is carried out under the protection of gas;
and/or, in the reduction reaction, the organic solvent is an ether solvent;
and/or the molar ratio of the lithium aluminum hydride to the compound shown in the formula II is 5-20: 1;
and/or, the reduction reaction is carried out in the presence of a lewis acid;
and/or the reaction temperature of the reduction reaction is 10-70 ℃.
12. The method of claim 10, wherein: in the reduction reaction, the organic solvent is tetrahydrofuran;
and/or the molar ratio of the lithium aluminum hydride to the compound shown in the formula II is 8-12: 1;
and/or the reduction reaction is carried out in the presence of Lewis acid, wherein the Lewis acid is aluminum trichloride;
and/or the reaction temperature of the reduction reaction is 30-50 ℃.
13. The method of claim 10, wherein: the reduction reaction is carried out in the presence of Lewis acid; the molar ratio of the Lewis acid to the compound shown as the formula II is 1-10: 1.
14. The method of claim 10, wherein: the reduction reaction is carried out in the presence of Lewis acid; the molar ratio of the Lewis acid to the compound shown as the formula II is 4-6: 1.
15. The method of claim 10, wherein: the preparation method of the compound shown in the formula II is method 1 or method 2:
the method 1 comprises the following steps: in an organic solvent, reacting a compound shown as a formula III withCarrying out coupling reaction as shown in the specification on an organic zinc reagent or an organic boron reagent in the presence of a palladium catalyst to obtain a compound as shown in a formula II; wherein the organic zinc reagent is Zn (R)2)2Or ZnR2Y and Y are chlorine, bromine or iodine; the organic boron reagent is R2B(OH)2
Figure FDA0002913653440000061
The method 2 comprises the following steps: in an organic solvent, carrying out an elimination reaction shown in the following formula on a compound shown in a formula III-2 in the presence of tert-butyl alcohol alkali metal salt and water to obtain a compound shown in a formula II; wherein, in the method 2, R2Is hydrogen;
Figure FDA0002913653440000071
16. the method of claim 15, wherein: in the method 1, the preparation method of the compound shown as the formula III comprises the following steps: in an organic solvent, mixing a compound shown as IV and R1Carrying out addition reaction on MgX as shown in the specification to obtain a compound shown in a formula III; wherein X is chlorine, bromine or iodine;
Figure FDA0002913653440000072
17. the method of claim 16, wherein: in the method 1, the preparation method of the compound shown as IV comprises the following steps: in an organic solvent, carrying out iodination reaction on a compound shown as a formula V and iodine in the presence of alkali to obtain a compound shown as a formula IV;
Figure FDA0002913653440000073
18. the method of claim 15, wherein: in the method 2, the preparation method of the compound shown as the formula III-2 comprises the following steps: in an organic solvent, a compound shown as V and R1MgX is subjected to addition reaction as shown in the specification to obtain a compound shown in a formula III-2; wherein X is chlorine, bromine or iodine;
Figure FDA0002913653440000081
19. the method of claim 17 or 18, wherein: in the method 1 or the method 2, the preparation method of the compound shown as the formula V comprises the following steps: in an organic solvent, carrying out cyclization reaction on a compound shown as a formula VI and a cobalt carbonyl reagent in a carbon monoxide atmosphere to obtain a compound shown as a formula V;
Figure FDA0002913653440000082
20. the method of claim 19, wherein: in the method 1 or the method 2, the preparation method of the compound shown as the formula VI comprises the following steps: reacting a compound shown as a formula VII with tert-butyl lithium in an organic solvent, and then reacting with trimethylchlorosilane in the presence of hexamethylphosphoric triamide to obtain a compound shown as a formula VI;
Figure FDA0002913653440000083
21. the method of claim 20, wherein: in the method 1 or the method 2, the preparation method of the compound shown as the formula VII comprises the following steps: in an organic solvent, carrying out substitution reaction on a compound shown as a formula VIII and trichloroethylene in the presence of sodium hydride as shown in the specification to obtain a compound shown as a formula VII;
Figure FDA0002913653440000091
22. the method of claim 15, wherein: in the method 1, the coupling reaction is carried out under the protection of gas;
and/or, in the method 1, in the coupling reaction, the organic solvent is an ether solvent;
and/or, in the method 1, when R is2When the compound is alkyl, an organic zinc reagent is adopted to react with the compound shown in the formula III;
and/or, in the method 1, when R is2When the aryl is aryl, reacting an organic boron reagent with a compound shown as a formula III;
and/or, in the method 1, in the coupling reaction, the molar ratio of the organic zinc reagent to the compound shown in the formula III is 2-8: 1;
and/or, in the method 1, in the coupling reaction, the molar ratio of the organoboron reagent to the compound shown in the formula III is 2-8: 1;
and/or, in the method 1, in the coupling reaction, the palladium catalyst is tetrakis (triphenylphosphine) palladium;
and/or, in the method 1, in the coupling reaction, the molar ratio of the palladium catalyst to the compound shown in the formula III is 0.02-0.3: 1;
and/or, in the method 1, the reaction temperature of the coupling reaction is 25-100 ℃; and/or, in the method 2, the elimination reaction is carried out under the protection of gas;
and/or in the method 2, in the elimination reaction, the organic solvent is a sulfone solvent;
and/or, in the method 2, in the elimination reaction, the tert-butyl alcohol alkali metal salt is sodium tert-butoxide and/or potassium tert-butoxide;
and/or, in the method 2, in the elimination reaction, the molar ratio of the tert-butanol alkali metal salt to the compound shown in the formula III-2 is 2.2-3.2: 1;
and/or, in the method 2, in the elimination reaction, the molar ratio of the water to the compound shown in the formula III-2 is 10-100: 1;
and/or, in the method 2, the reaction temperature of the elimination reaction is 25-100 ℃.
23. The method of claim 15, wherein: in the method 1, in the coupling reaction, the organic solvent is dioxane;
and/or, in the method 1, in the coupling reaction, the molar ratio of the organic zinc reagent to the compound shown in the formula III is 4-6: 1;
and/or, in the method 1, in the coupling reaction, the molar ratio of the organoboron reagent to the compound shown in the formula III is 4-6: 1;
and/or, in the method 1, in the coupling reaction, the molar ratio of the palladium catalyst to the compound shown in the formula III is 0.05-0.1: 1;
and/or, in the method 1, the reaction temperature of the coupling reaction is 70-90 ℃;
and/or, in the method 2, in the elimination reaction, the organic solvent is dimethyl sulfoxide;
and/or, in the method 2, in the elimination reaction, the molar ratio of the tert-butanol alkali metal salt to the compound shown in the formula III-2 is 3-3.2: 1;
and/or, in the method 2, in the elimination reaction, the molar ratio of the water to the compound shown in the formula III-2 is 30-40: 1;
and/or, in the method 2, the reaction temperature of the elimination reaction is 60-80 ℃.
24. The method of claim 16, wherein: in the method 1, the addition reaction is carried out under the protection of gas;
and/or, in the method 1, in the addition reaction, the organic solvent is an ether solvent;
and/or, in the method 1, in the addition reaction, the R1The molar ratio of MgX to the compound shown as IV is 1-2: 1;
and/or, in the method 1, the reaction temperature of the addition reaction is-30 ℃ to 5 ℃.
25. The method of claim 16, wherein: in the method 1, in the addition reaction, the organic solvent is diethyl ether;
and/or, in the method 1, in the addition reaction, the R1The molar ratio of MgX to the compound shown as IV is 1.5-2: 1;
and/or, in the method 1, the reaction temperature of the addition reaction is-20 ℃ to 0 ℃.
26. The method of claim 17, wherein: in the method 1, the iodination reaction is carried out under the protection of gas;
and/or, in the method 1, in the iodination reaction, the organic solvent is a mixed solvent of a nitrile solvent and a chlorinated hydrocarbon solvent;
and/or in the method 1, in the iodination reaction, the molar ratio of the iodine to the compound shown in the formula V is 1-6: 1;
and/or, in the method 1, in the iodination reaction, the base is an inorganic base;
and/or, in the method 1, the reaction temperature of the iodination reaction is 0-50 ℃.
27. The method of claim 17, wherein: in the iodination reaction, the organic solvent is a mixed solvent of a nitrile solvent and a chlorohydrocarbon solvent; wherein the volume ratio of the nitrile solvent to the chlorohydrocarbon solvent is 0.8-1.2: 1;
in the method 1, in the iodination reaction, the molar ratio of iodine to the compound shown in the formula V is 3-5: 1;
and/or, in the method 1, in the iodination reaction, the base is an alkali metal bicarbonate;
and/or, in the method 1, the reaction temperature of the iodination reaction is 10-30 ℃.
28. The method of claim 17, wherein: in the method 1, in the iodination reaction, the alkali is sodium bicarbonate and/or potassium bicarbonate.
29. The method of claim 18, wherein: in the method 2, the addition reaction is carried out under the protection of gas;
and/or, in the method 2, in the addition reaction, the organic solvent is an ether solvent;
and/or, in the method 2, in the addition reaction, the R1The molar ratio of MgX to the compound shown as V is 1-2: 1;
and/or, in the method 2, the reaction temperature of the addition reaction is-30 ℃ to 5 ℃.
30. The method of claim 18, wherein: in the method 2, in the addition reaction, the organic solvent is diethyl ether;
and/or, in the method 2, in the addition reaction, the R1The molar ratio of MgX to the compound shown as V is 1.5-2: 1;
and/or, in the method 2, the reaction temperature of the addition reaction is-20 ℃ to 0 ℃.
31. The method of claim 19, wherein: in the method 1 or the method 2, the cyclization reaction is carried out under the protection of gas;
and/or, in the method 1 or the method 2, in the cyclization reaction, the organic solvent is an aromatic hydrocarbon solvent;
and/or, in the method 1 or the method 2, in the cyclization reaction, the cobalt carbonyl reagent is BrCCo in the cyclization reaction3(CO)9
And/or, in the method 1 or the method 2, in the cyclization reaction, the molar ratio of the cobalt carbonyl reagent to the compound shown in the formula VI is 0.05-0.2: 1;
and/or, in the method 1 or the method 2, the pressure of the carbon monoxide in the cyclization reaction is 10-30 atm;
and/or, in the method 1 or the method 2, the reaction temperature of the cyclization reaction is 50-130 ℃.
32. The method of claim 19, wherein: in the method 1 or 2, in the cyclization reaction, the organic solvent is toluene;
and/or, in the method 1 or the method 2, in the cyclization reaction, the molar ratio of the cobalt carbonyl reagent to the compound shown in the formula VI is 0.1-0.2: 1;
and/or, in the method 1 or the method 2, the pressure of the carbon monoxide in the cyclization reaction is 20-30 atm;
and/or, in the method 1 or the method 2, the reaction temperature of the cyclization reaction is 90-120 ℃.
33. The method of claim 20, wherein: in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the organic solvent is an ether solvent;
and/or in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the molar ratio of tert-butyl lithium to the compound shown in the formula VII is 3-5: 1;
and/or in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the molar ratio of the trimethylchlorosilane to the compound shown in the formula VII is 3-5: 1;
and/or in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the molar ratio of hexamethylphosphoric triamide to the compound shown in the formula VII is 3-5: 1.
34. The method of claim 20, wherein: in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the organic solvent is tetrahydrofuran;
and/or in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the molar ratio of tert-butyl lithium to the compound shown in the formula VII is 4-5: 1;
and/or in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the molar ratio of the trimethylchlorosilane to the compound shown in the formula VII is 4-5: 1;
and/or in the method 1 or the method 2, in the preparation method of the compound shown in the formula VI, the molar ratio of hexamethylphosphoric triamide to the compound shown in the formula VII is 4-5: 1.
35. The method of claim 21, wherein: in the method 1 or the method 2, the substitution reaction is carried out under the protection of gas;
and/or in the method 1 or the method 2, in the substitution reaction, the organic solvent is a sulfone solvent;
and/or, in the method 1 or the method 2, in the substitution reaction, the molar ratio of the trichloroethylene to the compound shown in the formula VIII is 2-8: 1;
and/or, in the method 1 or the method 2, in the substitution reaction, the molar ratio of the sodium hydride to the compound shown in the formula VIII is 3-5: 1;
and/or, in the method 1 or the method 2, the reaction temperature of the substitution reaction is 20-100 ℃.
36. The method of claim 21, wherein: in the method 1 or 2, in the substitution reaction, the organic solvent is dimethyl sulfoxide;
and/or, in the method 1 or the method 2, in the substitution reaction, the molar ratio of the trichloroethylene to the compound shown in the formula VIII is 4-6: 1;
and/or, in the method 1 or the method 2, in the substitution reaction, the molar ratio of the sodium hydride to the compound shown in the formula VIII is 4-5: 1;
and/or, in the method 1 or the method 2, the reaction temperature of the substitution reaction is 50-70 ℃.
CN201910164735.0A 2019-03-05 2019-03-05 Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof Active CN109912663B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910164735.0A CN109912663B (en) 2019-03-05 2019-03-05 Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910164735.0A CN109912663B (en) 2019-03-05 2019-03-05 Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof

Publications (2)

Publication Number Publication Date
CN109912663A CN109912663A (en) 2019-06-21
CN109912663B true CN109912663B (en) 2021-06-08

Family

ID=66963431

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910164735.0A Active CN109912663B (en) 2019-03-05 2019-03-05 Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof

Country Status (1)

Country Link
CN (1) CN109912663B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112592340B (en) * 2020-12-23 2023-01-17 中国科学院上海有机化学研究所 Chiral azaspiroalkene salt compound and preparation method thereof
CN114773400B (en) * 2022-06-01 2024-04-26 中国科学院上海有机化学研究所 Rhodium complex, preparation method, intermediate and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101239991A (en) * 2002-12-05 2008-08-13 武田药品工业株式会社 Transition metal complex having diphosphine compound as ligand
US20080207942A1 (en) * 2005-09-16 2008-08-28 Kaiser-Wilhelm-Platz 1 Chiral Phosphoramidites
CN104744514A (en) * 2013-12-27 2015-07-01 中国科学院上海药物研究所 Chiral phosphorus alkene ligand, synthesis method and application thereof in asymmetric reaction
CN106040299A (en) * 2016-05-30 2016-10-26 北京理工大学 Chiral diene rhodium metal catalyst and preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101239991A (en) * 2002-12-05 2008-08-13 武田药品工业株式会社 Transition metal complex having diphosphine compound as ligand
US20080207942A1 (en) * 2005-09-16 2008-08-28 Kaiser-Wilhelm-Platz 1 Chiral Phosphoramidites
CN104744514A (en) * 2013-12-27 2015-07-01 中国科学院上海药物研究所 Chiral phosphorus alkene ligand, synthesis method and application thereof in asymmetric reaction
CN106040299A (en) * 2016-05-30 2016-10-26 北京理工大学 Chiral diene rhodium metal catalyst and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
过渡金属催化的碳氢键官能团化反应合成平面手性二茂铁化合物;黄家翩等;《有机化学》;20170915;第38卷;51-61页 *

Also Published As

Publication number Publication date
CN109912663A (en) 2019-06-21

Similar Documents

Publication Publication Date Title
CN109912663B (en) Oxygen-linked cyclopentadiene rhodium complex, preparation method, intermediate and application thereof
CN107382884B (en) Synthesis method of beta-iodo-N-alkoxy benzotriazole compound
JP6389307B2 (en) Method for producing aluminum catalyst
CN107188781B (en) Method for preparing isopulegol from citronellal
CN111848675B (en) Tetrahydroquinoline framework chiral phosphine-nitrogen ligand and preparation method and application thereof
CN109134460B (en) Synthesis method of beta-carboline compound
Li et al. Enantioselective Intramolecular Desymmetric α‐Addition of Cyclohexanone to Propiolamide Catalyzed by Sodium L‐Prolinate
CN112300072A (en) High-yield synthesis method of 5-iodoisoquinoline compounds
CN114591217B (en) Preparation method of 6, 6-dimethyl-3-azabicyclo- [3.1.0] -hexane and lactone intermediate thereof
CN111217809B (en) Chiral nitrogen-containing diene ligand and preparation method and application thereof
CN113149895B (en) Method for synthesizing isoquinolone compounds or pyridone compounds
CN110845291B (en) Method for catalytic reduction of alkyne into olefin by visible light induction
CN109096338B (en) Benzaphosphepillocenyl phosphine oxide ligand, complex containing same, preparation method and application
CN114832862B (en) Catalytic composition for coupling reaction and application of catalytic composition in preparation of isoquinoline-1, 3-dione compounds
CN115093313B (en) Multi-methyl substituted spiroindane derivative cyclopentadiene, rhodium complex, preparation method, intermediate and application thereof
CN109096337B (en) A kind of phospha indole derivatives, benzo phospha indole derivatives and preparation method thereof
CN109897039A (en) A method of preparing pyrrolo- [3,2,1-ij] quinolinone compounds
CN110683940B (en) Method for converting dibenzo [ c, e ] [1,2] oxathiane-6-oxide compound
CN114605273B (en) Method for synthesizing arylaminophenol compound by palladium-catalyzed CO-participated 1, 4-eneyne aromatization reaction
CN110467556B (en) Nucleophilic reaction method for catalyzing imine ions and acetophenone by nickel
CN109796372B (en) Method for preparing polysubstituted alkenyl amidine
ZENGİN et al. Synthesis of n-alkylnaphthalenes via semicarbazones
CN117447517A (en) Novel tridentate pincer ligand, ruthenium complex, preparation method thereof and application thereof in alcohol dehydrogenation preparation of ester
CN115745805A (en) Synthetic method of phenanthrene and naphthocycloheptene compounds
CN116554223A (en) Chiral biphosphine skeleton compound, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant